Trial Profile
Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2018 Status changed from recruiting to completed, according to the results published in the Japanese Journal of Clinical Oncology.
- 12 Dec 2015 Results of 46 patients enrolled till February 2013 were presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 15 Nov 2012 Planned end date changed from 1 Sep 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.